When researchers want to answer the question "does this treatment work?", a systematic review is one of the more rigorous tools available. You search the published literature in a structured way, apply consistent quality criteria, and draw conclusions from the combined evidence. In 2024, Ceballos-Laita and colleagues did exactly this for craniosacral therapy.
The review, published in Healthcare, covered 15 randomised controlled trials across both musculoskeletal conditions (like neck and back pain) and non-musculoskeletal ones. The question was direct: does CST produce measurable clinical benefits? The answer, across the trials they found, was no.
That's worth sitting with. It's also worth understanding what this kind of review can and can't tell you.
How the review was done
The researchers searched PubMed, Embase, and the Cochrane Library for randomised controlled trials assessing CST's effect on any condition. They applied pre-specified inclusion criteria — the protection against cherry-picking — and ended up with 15 trials.
Each trial was then assessed for methodological quality using standard risk-of-bias tools. The question is: how well was this study designed? Could the results be explained by something other than the treatment? Was randomisation done properly, were assessors blinded, was the analysis pre-specified?
Fourteen of the 15 included trials had a high risk of bias. That matters. The authors weren't working with a pool of well-designed trials that found no effect. They were working with trials that had real methodological weaknesses, which makes any conclusion — positive or negative — harder to be confident about.
What they found and what it means
Across all 15 trials and all conditions, the headline finding was that CST produced no measurable clinical benefits. This held for musculoskeletal and non-musculoskeletal presentations alike. No subgroup — no specific condition or population — showed a convincing positive result.
For someone weighing up CST before trying it, this is genuinely useful information. The RCT evidence base, judged by the standards of conventional clinical research, isn't strong. There's no convincing body of trial data saying: this treatment reliably helps people with condition X.
What the finding doesn't capture is the full picture of why people seek out CST and report benefit. The therapy offers sustained, careful attention in a quiet room, often over a series of sessions. The therapeutic relationship — being listened to, being attended to — matters in ways RCTs aren't usually built to measure. And individual variation is huge. What doesn't show up as a statistically significant average effect across a heterogeneous group can still be very helpful for a specific person.
Holding evidence and experience together
The honest position on CST evidence goes something like this. The trial evidence is currently weak. The trials that exist have design limitations that make their results hard to interpret. Both true. It's also true that many people find real value in CST sessions, and that experienced practitioners report consistent patterns across years of clinical work.
These aren't straightforwardly compatible, but they're not necessarily in conflict either. Weak scientific evidence doesn't confirm or refute individual experience. It just means we don't yet have the kind of large, well-designed trial data that would support strong population-level claims.
If you're considering CST and want to think it through carefully, this review is part of the picture. So is the experience of someone you trust who found benefit. So is your own first session. Evidence should inform your approach, not replace your own judgement.
The Ceballos-Laita review is the most current comprehensive assessment of CST's evidence base, and its finding of no measurable benefits across 15 RCTs deserves honest acknowledgment. It's one piece of a larger picture. But it's a piece worth knowing about.